KRYSTEXXA for Amgen

As a UI Designer at Epsilon (a Publicis Groupe-owned company), I had the opportunity to work on the website design for KRYSTEXXA (pegloticase) - a medication used to treat chronic gout in adult patients who have not responded to conventional therapies.

My work on the website has resulted in significant improvements in user engagement and conversion rates, including a 50% increase in monthly users (from 20,000 to 30,000) and a 15% improvement in the conversion rate.

Key improvements in the user journey stages include a 15% increase in the number of patients starting KRYSTEXXA and a 50% rise in support requests.

These metrics highlight the effectiveness of our user-centered design approach, leading to higher customer satisfaction and an increased number of patients.